Honolulu Star-Advertiser

Tuesday, November 5, 2024 74° Today's Paper


Top News

Weighed down by bad reviews, ‘Morbius’ opens with $39.1M

ASSOCIATED PRESS
                                This image released by Sony Pictures shows Jared Leto in a scene from “Morbius.”

ASSOCIATED PRESS

This image released by Sony Pictures shows Jared Leto in a scene from “Morbius.”

NEW YORK >> Sony Pictures’ Marvel adaptation “Morbius” landed with dismal reviews but still managed to debut with $39.1 million in ticket sales, according to studio estimates today.

That was enough to easily hand “Morbius,” starring Jared Leto as a vampire-transforming biochemist, the top spot at the box office — even though it was an uncharacteristically low debut for a Marvel movie. Sony’s last movie to launch a Marvel character, 2018’s “Venom,” opened in 2018 with double the ticket sales.

But “Morbius” also drew unusually bad reviews for a Marvel release. On Rotten Tomatoes, it sits with easily the worst score for a Marvel film at 17% fresh. “Venom” (30%) wasn’t a hit with critics, either. But given that forecasts had ranged closer to a $50 million opening weekend for “Morbius,” the poor word-of-mouth and worse reviews likely cut into its receipts.

“This is a weak opening by Marvel’s exceptional standard for launching a new superhero series,” said David A. Gross, who runs the consulting firm Franchise Entertainment Research. “The weekend figure is well below average for a Marvel first episode, and below average compared with a DC Comics new series, as well.”

Still, “Morbius,” delayed several times by the pandemic, was budgeted somewhat modestly for a comic-book film, costing $75 million to produce. Audiences also gave it a low grade — C+ from CinemaScore — though moviegoers still seemed to like it more than critics. The audience score from Rotten Tomatoes for the Daniel Espinosa-directed film is 69% fresh.

Overseas, “Morbius” grossed $44.9 million over the weekend, for an $84 million global haul.

Still, it will be hard for “Morbius” to get anywhere close to Sony’s recent Marvel successes. The last two were box-office hits: “Spider-Man: No Way Home” has grossed nearly $1.9 billion worldwide, while last year’s “Venom 2” took in $502 million globally.

Last week’s top film, the Sandra Bullock-Channing Tatum rom-com adventure “The Lost City,” slid to second place with $14.8 million in its second week. With a two-week total of $54.6 million, “The Lost City” is performing much better than other recent entries in the genre.

Following the Academy Awards, Apple put best picture-winner “CODA” into more than 500 theaters. The film, which debuted on Apple TV+ last August, became the first movie from a streaming service ever to take Hollywood’s top honor. Apple didn’t share ticket-sales figures Sunday, making “CODA” the first best-picture winner without any recorded U.S. box office.

Also working against “Morbius”: The box office is getting busier. While no new wide releases went up against the Sony release this weekend, the coming weeks bring the releases of “Sonic the Hedgehog 2,” “Ambulance” and “Fantastic Beasts: The Secret of Dumbledore.” The next Marvel movie, “Doctor Strange in the Multiverse of Madness,” comes from the Walt Disney Co. on May 6.

Estimated ticket sales for Friday through today at U.S. and Canadian theaters, according to Comscore. Final domestic figures will be released Monday.

1. “Morbius,” $39.1 million.

2. “The Lost City,” $14.8 million.

3. “The Batman,” $10.8 million.

4. “Uncharted,” $3.6 million.

5. “Jujutsu Kaisen 0,” $1.9 million.

6. “RRR,” $1.6 million.

7. “Spider-Man: No Way Home,” $1.4 million.

8. “Dog,” $1.3 million.

9. “X,” $1 million.

10. “Everything Everywhere All at Once,” $1 million.

By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines. Having trouble with comments? Learn more here.